findmyKOL
Clinical trialNCT05816499UnknownPhase 1/PHASE2Interventional

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)

SponsorShanghai Chest HospitalEnrollment50NSCLC Stage IIIBNSCLC Stage IIICNSCLC Stage IV
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Lejie Cao

    Hefei, Anhui, China

  • Jing Wang

    Qingdao, Shandong, China

  • Zhuang Yu

    Qingdao, Shandong, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

  • Jianya Zhou

    Hangzhou, Zhejiang, China

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
16 Feb 2023
Primary completion
30 Dec 2024
Completion
30 Dec 2025
Last update posted
17 Jun 2024
Registered enrollment
50
Registry id
NCT05816499
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.